Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH)

The CLARITY survey, the findings of which were published in the Pulmonary Circulation April 2024 issue (link), aimed to collect data on current chronic thromboembolic pulmonary hypertension (CTEPH) diagnosis, treatment, and management, and to identify unmet medical needs. Conducted from September 2021 to May 2022, the survey targeted hospital-based medical specialists via Scientific Societies and […]

Recent report reveals wide regional variability in access to pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) for chronic thromboembolic pulmonary hypertension (CTEPH) Read Post »

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024

Sotatercept, an activin signaling inhibitor, has been recently approved by the FDA for treating pulmonary arterial hypertension (PAH) (see our recent article about the FDA approval at this link), based on two pivotal clinical trials. The authors of the article titled “How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial

“How We Do It: Using Sotatercept in the Care of Patients with Pulmonary Arterial Hypertension”, CHEST Journal, July 14, 2024 Read Post »

The key role of patient associations highlighted during discussions at the 5th French Pulmonary Hypertension Network Meeting, “Respiratory Medicine and Research”, Volume 86, 2024

The 5th French Pulmonary Hypertension Network Meeting, convened in Le Kremlin-Bicêtre, France, in 2023, served as a platform to examine current evidence and outstanding questions in pulmonary hypertension, particularly in the context of the recently published 2022 ESC/ERS Guidelines. The French Network is composed of some of France’s key experts in the field of pulmonary

The key role of patient associations highlighted during discussions at the 5th French Pulmonary Hypertension Network Meeting, “Respiratory Medicine and Research”, Volume 86, 2024 Read Post »

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK

The first-in-class pulmonary arterial hypertension drug sotatercept was approved in March 2024 by the Food and Drug Administration (FDA) in the USA and the approval of the European Medicines Agency (EMA) is expected in the next few months. The UK Pulmonary Hypertension Association, PHA UK, has put together a short video, with its Chair Dr

The UK Pulmonary Hypertension Association Chair, Dr Iain Armstrong, explains what happens next with sotatercept and what will be considered when it comes to making decisions for the UK Read Post »

Food and Drug Administration (FDA) tentatively approves generic selexipag by injection for the treatment of pulmonary arterial hypertension, “Pulmonary Hypertension News, July 15, 2024

A recent article in “Pulmonary Hypertension News” reports on the tentative approval of Alembic Pharmaceuticals’ generic selexipag as pulmonary arterial hypertension treatment for pulmonary arterial hypertension. Alembic’s generic selexipag contains the same chemical substance as an approved treatment, Uptravi for injection, sold by Johnson & Johnson. Selexipag is a prostacyclin receptor agonist that leads to

Food and Drug Administration (FDA) tentatively approves generic selexipag by injection for the treatment of pulmonary arterial hypertension, “Pulmonary Hypertension News, July 15, 2024 Read Post »

Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review

Adherence to medication (MA) is crucial in chronic diseases, but its impact on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) has been less studied. A recent study reviews the adherence patterns, identifies factors linked to low adherence, and examines the associated outcomes in these patients. Methods A systematic review was conducted across

Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review Read Post »

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial

Aerovate Therapeutics has announced that its pulmonary arterial hypertension (PAH) candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial. The Phase IIb portion of the IMPAHCT trial aimed to assess three different doses of AV-101, a novel dry powder inhaled formulation of imatinib. The primary endpoint tested

Aerovate Therapeutics announces that its pulmonary arterial hypertension candidate AV-101 failed to meet its primary endpoint in the Phase IIb portion of the IMPAHCT trial Read Post »

Insights and connections: highlights from the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024

The Alliance for Pulmonary Hypertension team – Ioanna Alysandratou, Pisana Ferrari, Mélanie Gallant-Dewavrin, Louise Bouman – van der Waal, Hans-Dieter Kulla and Laure Rosé – is back from the 7th World Symposium on Pulmonary Hypertension in Barcelona. Attending the World Symposium on Pulmonary Hypertension was an incredibly exciting and enriching experience. The scientific sessions were

Insights and connections: highlights from the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024 Read Post »

Setting the Tone: The Role of Patient Voices at the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024

In his concluding remarks at the 7th World Symposium on Pulmonary Hypertension, Prof. Marc Humbert highlighted the impressive diversity and scale of the event. The symposium hosted 1,697 participants, including 1,102 healthcare professionals, from various specialties, 124 task force members, and 471 industry staff, from over 60 countries. This diversity underscores the global effort and

Setting the Tone: The Role of Patient Voices at the World Symposium on Pulmonary Hypertension, Barcelona, 29.6-1.7, 2024 Read Post »

The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Winrevair (sotatercept)

On 28 June 2024 the European Medicines Agency has issued a press release to say that the CHMP (human medicines committee) has recommended granting a marketing authorisation in the European Union (EU) for Winrevair (sotatercept) to treat adult patients with pulmonary arterial hypertension (PAH), in combination with other specific PAH therapies, to improve exercise capacity. This is the first step

The Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorisation for Winrevair (sotatercept) Read Post »

The UPHILL study investigates whether a change in diet can improve the quality of life of pulmonary arterial hypertension patients, Pulmonary Circulation, May 27, 2023

The UPHILL study investigated whether a diet could improve the quality of life (QOL) for patients with pulmonary arterial hypertension (PAH). An important part of this was monitoring the nutritional status. Nutritional status is not only what someone eats and drinks, but also the vitamin and mineral levels in the blood. Several notable findings emerged

The UPHILL study investigates whether a change in diet can improve the quality of life of pulmonary arterial hypertension patients, Pulmonary Circulation, May 27, 2023 Read Post »

Unraveling the genetics of pulmonary hypertension webinar

“Unraveling the Genetics of Pulmonary Hypertension” explored the genetic underpinnings of this complex disease. Our panel of experts, including a patient, explored the latest research, information on genetic mutations associated with pulmonary hypertension, and practical guidance on genetic counseling and testing. Speakers Prof David Montani, Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National

Unraveling the genetics of pulmonary hypertension webinar Read Post »

Interesting analysis of the prognostic value of the “Multicomponent Improvement” (MCI) endpoint in patients with pulmonary arterial hypertension (PAH) treated with sotatercept

The Multicomponent Improvement” (MCI) endpoint is a composite endpoint measuring improvement in 6-minute walk distance, reduction or maintenance of low N-terminal pro-BNP levels, and improvement or maintenance of WHO functional class I or II. The American Journal of Respiratory and Critical Care Medicine has published the abstract of a session at the American Thoracic Society

Interesting analysis of the prognostic value of the “Multicomponent Improvement” (MCI) endpoint in patients with pulmonary arterial hypertension (PAH) treated with sotatercept Read Post »

Less than 2 weeks to go to the World Symposium on Pulmonary Hypertension. If you are attending come meet the Alliance for Pulmonary Hypertension team at their booth!

The Alliance for Pulmonary Hypertension will have six delegates attending the World Symposium on Pulmonary Hypertension taking place in Barcelona 29.6-1.7 2024. Visit their booth and meet the team! Ioanna Alysandratou Ιωάννα Αλυσανδράτου President of the Hellenic Community for Pulmonary Hypertension Louise Bouman – van der Waal Chair of the Stichting Pulmonale Hypertensie / PH

Less than 2 weeks to go to the World Symposium on Pulmonary Hypertension. If you are attending come meet the Alliance for Pulmonary Hypertension team at their booth! Read Post »

Special issue of “Transplant International” delves into the multifaceted ethical and legal complexities surrounding organ donation and transplantation, June 2024

The latest special issue of “Transplant International,” titled “Ethical and Legal Aspects of Organ Donation and Transplantation,” tackles the intricate challenges inherent in organ donation and transplantation. Edited by Frederike Ambagtsheer, Coby Annema, David Paredes-Zapata and John Forsythe, this collection comprises 16 articles penned by global experts, spanning the years 2022 to 2024. These articles

Special issue of “Transplant International” delves into the multifaceted ethical and legal complexities surrounding organ donation and transplantation, June 2024 Read Post »

New study suggests that QOL measurements add prognostic information and should be used in routine pulmonary arterial hypertension assessment and management, “Pulmonary Circulation”, June 2, 2024

A recent study, conducted at the Hunter-New England pulmonary arterial hypertension (PAH) clinic in Newcastle, Australia, investigated the assessment of patient-reported outcome measures (PROs) and quality of life (QOL) in patients in WHO Group 1, pulmonary arterial hypertension. It aimed to determine if QOL scores, measured using both disease-specific (PAH-SYMPACT©) and general (EQ-5D-5L™) tools, could

New study suggests that QOL measurements add prognostic information and should be used in routine pulmonary arterial hypertension assessment and management, “Pulmonary Circulation”, June 2, 2024 Read Post »

“Fundamentals of Genetic Testing”, a live webinar organised by the Pulmonary Hypertension Association (PHA) in collaboration with with partners TBX4life and Fundación Contra la Hipertensión Pulmonar, June 11, 2024

The Pulmonary Hypertension Association (PHA) is holding a webinar of “Fundamentals of Genetic Testing“ on Tuesday, June 11, at 2 p.m. EDT/ 6 p.m. UTC in collaboration with TBX4Life and Fundación Contra la Hipertensión Pulmonar Featured topics include The webinar will be available in English and Spanish. Speakers Harm Jan Bogaard, MD, PhDProfessor of Experimental Pulmonary MedicinePulmonologist, Department

“Fundamentals of Genetic Testing”, a live webinar organised by the Pulmonary Hypertension Association (PHA) in collaboration with with partners TBX4life and Fundación Contra la Hipertensión Pulmonar, June 11, 2024 Read Post »

Sharing best practices in chronic thromboembolic pulmonary hypertension surgical and interventional treatments: insights from two world experts

The Alliance for Pulmonary Hypertension (AfPH) places a strong emphasis on the sharing of knowledge and best practices as a means to empower patients and family members and advance the understanding and treatment of pulmonary hypertension. This is the rationale behind the creation of the Pulmonary Hypertension Knowledge Sharing Platform, an open, inclusive, and dynamic

Sharing best practices in chronic thromboembolic pulmonary hypertension surgical and interventional treatments: insights from two world experts Read Post »

Pioneering scientists who self-experiment new potential treatments or interventions: two remarkable stories in pulmonary hypertension

The history of scientists self-experimenting is filled with fascinating stories. In 1799, a young English chemist, Humphry Davy, later Sir Humphry, discovered “laughing gas” by inhaling nitrous oxide in a sealed box. In the late 1800s, German surgeon August Bier tested spinal anesthesia by injecting himself with cocaine. In the 1940s, American virologist and medical

Pioneering scientists who self-experiment new potential treatments or interventions: two remarkable stories in pulmonary hypertension Read Post »

“Congenital heart disease and pulmonary hypertension”, an Alliance for Pulmonary Hypertension live webinar

Transcript “CONGENITAL HEART DISEASE AND PULMONARY HYPERTENSION”, MAY 18, 2024 NB. This transcript can be translated into your preferred language – use orange button at the bottom centre of this page to select it (slides are not translatable). DISCLAIMER: Despite every effort to ensure the accuracy of this transcript, we strongly encourage all visitors to consult with

“Congenital heart disease and pulmonary hypertension”, an Alliance for Pulmonary Hypertension live webinar Read Post »

TRANSLATE »
Scroll to Top